先健科技(01302.HK)G-Branch™获药监局正式注册批准

Core Viewpoint - The announcement by Xianjian Technology (01302.HK) regarding the approval of the G-Branch™ thoracoabdominal aortic stent-graft system by the National Medical Products Administration of China signifies a significant advancement in the treatment of thoracoabdominal aortic aneurysms (TAAA) [1] Group 1 - The G-Branch™ system is developed in collaboration with Professor Guo Wei's team from the First Medical Center of the Chinese People's Liberation Army General Hospital [1] - The product is specifically designed for the treatment of TAAA involving the celiac trunk, superior mesenteric artery, and bilateral renal arteries [1] - The system enables complete endovascular reconstruction of thoracoabdominal aortic aneurysms [1]